Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21249758 | 0.91 | CYP2D6 (0.37) | CYP2D6HRH3 | |
| SCHEMBL2603296 | 0.90 | CYP2D6 (0.45) | CYP2D6CHRNA7KDM4EMEN1ALDH1A1 | |
| SCHEMBL21249811 | 0.88 | CYP2D6 (0.34) | CYP2D6CHRNA7 | |
| SCHEMBL21965035 | 0.86 | CYP2D6 (0.35) | CYP2D6CHRNA7HRH3 | |
| SCHEMBL4473518 | 0.81 | LIPE (0.33) | CYP2D6HRH3 | |
| SCHEMBL16980430 | 0.77 | CYP2D6 (0.37) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18471534 | 0.77 | CYP2D6 (0.37) | CYP2D6CHRNA7HRH3 | |
| SCHEMBL20111959 | 0.77 | CYP2D6 (0.41) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL24576857 | 0.76 | CYP2D6 (0.39) | CYP2D6CHRNA7KDM4EMEN1ALDH1A1 | |
| SCHEMBL2603309 | 0.76 | CYP2D6 (0.39) | CYP2D6CHRNA7KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2014037340-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CYP2D6 955/4885CHRNA7 1599/4885KDM4E 3805/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | CYP2D6 4859/4885CHRNA7 2755/4885KDM4E 3145/4885 |
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | PTPN5, PTPN1, PTPN2 | CYP2D6 3885/4885CHRNA7 4848/4885KDM4E 1041/4885 |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | CYP2D6 646/4885CHRNA7 2734/4885KDM4E 2053/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | CYP2D6 437/4885CHRNA7 3035/4885KDM4E 2261/4885 |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | CYP2D6 646/4885CHRNA7 2734/4885KDM4E 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.